Page last updated: 2024-08-24

cephalosporin c and rpx7009

cephalosporin c has been researched along with rpx7009 in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (11.11)24.3611
2020's8 (88.89)2.80

Authors

AuthorsStudies
Ammerman, NC; Kaushik, A; Kreiswirth, BN; Lamichhane, G; Lee, J; Martins, O; Nuermberger, EL; Parrish, NM1
Millar, BC; Moore, JE; Moore, RE1
Pregnolato, M; Taccani, M; Terreni, M1
Belcher, R; Zobell, JT1
Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS1
Bianco, G; Boattini, M; Casale, R; Cavallo, R; Comini, S; Costa, C; Iannaccone, M1
Amadesi, S; Ambretti, S; Gaibani, P; Lazzarotto, T1
Hsueh, PR; Lee, YL1
Hsueh, PR; Ko, WC; Lee, YL1

Reviews

1 review(s) available for cephalosporin c and rpx7009

ArticleYear
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.
    Molecules (Basel, Switzerland), 2021, May-02, Volume: 26, Issue:9

    Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Cefiderocol; Cephalosporins; Chemistry, Pharmaceutical; Clostridioides difficile; Clostridium Infections; Drug Design; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Meropenem; Neisseria gonorrhoeae; Nitroimidazoles; Sisomicin; Tetracyclines

2021

Other Studies

8 other study(ies) available for cephalosporin c and rpx7009

ArticleYear
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:3

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Boronic Acids; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous

2019
Antimicrobial susceptibility of plastic-associated bacteria isolated from the ocean to novel antibiotics (delafloxacin, meropenem/vaborbactam, ceftolozane/tazobactam, ceftobiprole) - Can environmental bacteria be predictors of persistence of antibiotic ac
    International journal of hygiene and environmental health, 2020, Volume: 226

    Topics: Antarctic Regions; Anti-Bacterial Agents; Bacteria; Boronic Acids; Cephalosporins; Drug Resistance, Microbial; Fluoroquinolones; Islands; Meropenem; Oceans and Seas; Plastics; Polystyrenes; Tazobactam

2020
Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: Meropenem-vaborbactam and cefiderocol.
    Pediatric pulmonology, 2021, Volume: 56, Issue:9

    Topics: Anti-Bacterial Agents; Boronic Acids; Cefiderocol; Cephalosporins; Child; Cystic Fibrosis; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem

2021
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 113

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam

2021
Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2022, Volume: 41, Issue:4

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; COVID-19; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests

2022
Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient.
    Journal of global antimicrobial resistance, 2022, Volume: 30

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; Critical Illness; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests

2022
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
    The Journal of infection, 2023, Volume: 87, Issue:1

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2023
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
    International journal of antimicrobial agents, 2023, Volume: 62, Issue:2

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2023